GRI

GRI Bio, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website gribio.com
Employees(FY) 1
ISIN US3622AW2059

Performance

+2.64%

1W

-19.74%

1M

-59.62%

3M

-94.36%

6M

-84.41%

YTD

-98.95%

1Y

Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Advanced Technical Analysis

Technical Analysis of GRI 2024-05-10

Overview:

In analyzing the technical indicators for GRI stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and recommendations for pote...

See more ...

Recent News & Updates

2024-05-13 21:05
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase(Globenewswire)
2024-05-12 22:54
GRI Stock Earnings: GRI Bio Reported Results for Q1 2024(Investorplace)
2024-05-12 20:00
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-04-28 20:45
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity(Globenewswire)
2024-04-24 21:15
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar(Globenewswire)
2024-04-15 20:35
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent(Globenewswire)
2024-04-07 20:35
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference(Globenewswire)
2024-03-31 19:35
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-27 21:00
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference(Globenewswire)
2024-03-13 20:45
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators(Globenewswire)
2024-03-03 19:30
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom(Globenewswire)
2024-02-01 19:55
Why Is GRI Bio (GRI) Stock Down 21% Today?(Investorplace)
2024-02-01 19:00
GRI Bio Announces Pricing of $5.5 Million Public Offering(Globenewswire)
2024-01-25 19:05
GRI Bio Announces Reverse Stock Split(Globenewswire)
2023-12-06 00:47
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment(Yahoo Finance)
2023-12-04 20:05
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF )(Globenewswire)
2023-11-26 19:35
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ( iNKT ) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF )(Globenewswire)
2023-11-14 19:05
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)
2023-10-30 20:45
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases(Globenewswire)
2023-10-18 20:45
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference(Globenewswire)
2023-10-17 22:00
JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023(Accesswire)
2023-10-16 20:35
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression(Globenewswire)
2023-10-10 21:05
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference(Globenewswire)
2023-10-04 20:45
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions(Globenewswire)
2023-09-28 21:00
September Is Pulmonary Fibrosis Awareness Month: Heres What One Company Is Doing To Develop A Treatment For This Deadly Disease(Accesswire)
2023-09-05 21:05
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference(Yahoo Finance)
2023-08-31 21:15
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?(Yahoo Finance)
2023-08-28 23:06
GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign(Yahoo Finance)
2023-08-24 21:00
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus(Yahoo Finance)
2023-08-22 21:00
GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR(Yahoo Finance)

Page 1 of 2

previousnext